CSBR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Champions Oncology Inc (CSBR) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. The technical indicators are neutral to bearish, options data shows limited activity, and the company's financial performance has significantly deteriorated in the latest quarter. With no positive news or catalysts and no recent signals from Intellectia Proprietary Trading Signals, it is better to hold off on investing in this stock at this time.
The MACD is slightly positive but contracting, RSI is neutral at 41.303, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support levels are at $5.619 and $5.421, with resistance at $5.94 and $6.261. Overall, the technical indicators suggest a neutral to bearish trend.
NULL identified. There is no recent news, no positive financial trends, and no significant insider or hedge fund activity.
The company's financial performance has deteriorated significantly, with revenue down 2.82% YoY, net income down 106.21% YoY, and EPS down 106.45% YoY. Gross margin has also dropped by 23.74%. Additionally, no recent congress trading data or influential figure activity has been reported.
In Q3 2026, the company's revenue dropped to $16.56M (-2.82% YoY), net income dropped to -$279K (-106.21% YoY), EPS fell to -$0.02 (-106.45% YoY), and gross margin declined to 46.65% (-23.74% YoY). These metrics indicate significant financial deterioration.
No recent analyst ratings or price target updates are available for CSBR.
